KR102832078B1 - 항-글리코-muc1 항체 및 이의 용도 - Google Patents

항-글리코-muc1 항체 및 이의 용도 Download PDF

Info

Publication number
KR102832078B1
KR102832078B1 KR1020237040745A KR20237040745A KR102832078B1 KR 102832078 B1 KR102832078 B1 KR 102832078B1 KR 1020237040745 A KR1020237040745 A KR 1020237040745A KR 20237040745 A KR20237040745 A KR 20237040745A KR 102832078 B1 KR102832078 B1 KR 102832078B1
Authority
KR
South Korea
Prior art keywords
antibody
antigen
glyco
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237040745A
Other languages
English (en)
Korean (ko)
Other versions
KR20230165874A (ko
Inventor
세이어 화이트
Original Assignee
고 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고 테라퓨틱스, 인크. filed Critical 고 테라퓨틱스, 인크.
Publication of KR20230165874A publication Critical patent/KR20230165874A/ko
Application granted granted Critical
Publication of KR102832078B1 publication Critical patent/KR102832078B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G01N33/57492—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Oncology (AREA)
KR1020237040745A 2017-10-24 2017-10-24 항-글리코-muc1 항체 및 이의 용도 Active KR102832078B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2017/058036 WO2019083506A1 (en) 2017-10-24 2017-10-24 ANTI-GLYCO-MUC1 ANTIBODIES AND USES THEREOF
KR1020207014390A KR102608763B1 (ko) 2017-10-24 2017-10-24 항-글리코-muc1 항체 및 이의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207014390A Division KR102608763B1 (ko) 2017-10-24 2017-10-24 항-글리코-muc1 항체 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20230165874A KR20230165874A (ko) 2023-12-05
KR102832078B1 true KR102832078B1 (ko) 2025-07-08

Family

ID=66247577

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237040745A Active KR102832078B1 (ko) 2017-10-24 2017-10-24 항-글리코-muc1 항체 및 이의 용도
KR1020207014390A Active KR102608763B1 (ko) 2017-10-24 2017-10-24 항-글리코-muc1 항체 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207014390A Active KR102608763B1 (ko) 2017-10-24 2017-10-24 항-글리코-muc1 항체 및 이의 용도

Country Status (10)

Country Link
EP (1) EP3700936A4 (cg-RX-API-DMAC7.html)
JP (2) JP7358367B2 (cg-RX-API-DMAC7.html)
KR (2) KR102832078B1 (cg-RX-API-DMAC7.html)
CN (1) CN111479828B (cg-RX-API-DMAC7.html)
AU (1) AU2017436815B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020008001A2 (cg-RX-API-DMAC7.html)
CA (1) CA3078812A1 (cg-RX-API-DMAC7.html)
IL (1) IL274202A (cg-RX-API-DMAC7.html)
MX (1) MX2020004220A (cg-RX-API-DMAC7.html)
WO (1) WO2019083506A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102832078B1 (ko) * 2017-10-24 2025-07-08 고 테라퓨틱스, 인크. 항-글리코-muc1 항체 및 이의 용도
CN116322770A (zh) * 2020-07-31 2023-06-23 R·P·舍勒科技有限责任公司 对粘蛋白-1特异的抗体及其使用方法
US20250129180A1 (en) * 2021-08-27 2025-04-24 Peptron, Inc. Novel anti-muc1 antibody and use thereof
WO2023121448A1 (en) * 2021-12-21 2023-06-29 Merus N.V. Binding domains against cancer-associated muc1
CN114796498A (zh) * 2022-01-27 2022-07-29 中国农业大学 抑制muc1糖基化修饰的物质在提高乳腺癌细胞对抗乳腺癌药物的敏感度中的应用
WO2024213106A1 (zh) * 2023-04-13 2024-10-17 江苏恒瑞医药股份有限公司 特异性结合egfr和muc1的抗原结合分子、其药物偶联物及其医药用途
WO2026046336A1 (zh) * 2024-08-29 2026-03-05 江苏恒瑞医药股份有限公司 Trop2/MUC1结合分子及医药用途
WO2026132383A2 (en) 2024-12-20 2026-06-25 F. Hoffmann-La Roche Ag ANTIBODIES BINDING TO Tn-MUC-1
WO2026132145A1 (en) 2024-12-20 2026-06-25 F. Hoffmann-La Roche Ag Antibodies binding to tn-muc-1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005474A1 (en) * 2003-01-23 2015-01-01 Glycotope Gmbh Recognition molecules for the treatment and detection of tumors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075110A2 (en) * 2000-03-30 2001-10-11 Dyax Corp. Mucin-1 specific binding members and methods of use thereof
JP2010505775A (ja) * 2006-10-04 2010-02-25 クーベンハヴンス・ユニヴェルシテット Ｍｕｃ１に対する癌特異的な免疫反応の産生及び癌特異的ｍｕｃ１抗体
EP2014302A1 (en) * 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
CA2707689A1 (en) * 2007-12-05 2009-06-11 Kyowa Hakko Kirin Co., Ltd. Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
CA2741798A1 (en) * 2008-10-28 2010-05-06 Shionogi & Co., Ltd. Anti-muc1 antibody
EP2281844A1 (en) * 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015120180A1 (en) * 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
JP6476170B2 (ja) * 2014-04-28 2019-03-06 医化学創薬株式会社 抗ｍｕｃ１抗体又はその抗原結合性断片及びその用途
KR102832078B1 (ko) * 2017-10-24 2025-07-08 고 테라퓨틱스, 인크. 항-글리코-muc1 항체 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005474A1 (en) * 2003-01-23 2015-01-01 Glycotope Gmbh Recognition molecules for the treatment and detection of tumors

Also Published As

Publication number Publication date
CN111479828A (zh) 2020-07-31
JP7358367B2 (ja) 2023-10-10
WO2019083506A1 (en) 2019-05-02
EP3700936A4 (en) 2021-05-26
EP3700936A1 (en) 2020-09-02
AU2017436815B2 (en) 2025-05-29
KR102608763B1 (ko) 2023-11-30
CA3078812A1 (en) 2019-05-02
KR20200067885A (ko) 2020-06-12
JP7849340B2 (ja) 2026-04-21
AU2017436815A1 (en) 2020-04-23
JP2021510307A (ja) 2021-04-22
JP2024001073A (ja) 2024-01-09
MX2020004220A (es) 2020-10-05
CN111479828B (zh) 2024-07-05
IL274202A (en) 2020-06-30
KR20230165874A (ko) 2023-12-05
BR112020008001A2 (pt) 2020-10-20

Similar Documents

Publication Publication Date Title
JP7859981B2 (ja) 抗グリコｃｄ４４抗体およびその使用
JP7849340B2 (ja) 抗グリコｍｕｃ１抗体およびその使用
US12065504B2 (en) Anti-glyco-MUC1 antibodies and their uses
US20250304716A1 (en) Anti-glyco-muc1 antibodies and their uses
KR20220002967A (ko) 항 mertk 항체 및 이의 사용 방법
JP2024534910A (ja) 抗グリコｌａｍｐ１抗体およびその使用
JP2024536722A (ja) 抗グリコｃｍｅｔ抗体およびその使用
JP2024531915A (ja) 抗グリコｍｕｃ抗体およびその使用
US20250326855A1 (en) Anti-glyco-cd44 antibodies and their uses
HK40114974A (en) Anti-glyco-muc4 antibodies and their uses
CN118354788A (zh) 抗糖-muc4抗体及其用途

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000